Jump to Main Contents
研究所ロゴ

Home > Organization > Divisions and Independent Research Units > Group for Independent Research Unit > Laboratory of Fundamental Oncology > research activities

research activities

Original research papers

2017

  1. Masahiro Takikawa and Rieko Ohki (corresponding author). A vicious partnership between AKT and PHLDA3 to facilitate neuroendocrine tumors. Cancer Science, in press.

2016

  1. A novel p53 target gene FUCA1 encodes a fucosidase and regulates growth and survival of cancer cells. Issei Ezawa, Yuichiro Sawai, Tatsuya Kawase, Atsushi Okabe, Shuichi Tsutsumi, Hitoshi Ichikawa, Yuka Kobayashi, Fumio Tashiro, Hideo Namiki, Tadashi Kondo, Kentaro Semba, Hiroyuki Aburatani, Yoichi Taya, Hitoshi Nakagama and Rieko Ohki. (corresponding author) Cancer Science, 107(6):734-45, 2016.
  2. Yoshinori Asano, Tatsuya Kawase, Atsushi Okabe, Shuichi Tsutsumi, Hitoshi Ichikawa, Satoko Tatebe, Issay Kitabayashi, Fumio Tashiro, Hideo Namiki, Tadashi Kondo, Kentaro Semba, Hiroyuki Aburatani, Yoichi Taya, Hitoshi Nakagama and Rieko Ohki (corresponding author). IER5 generates a novel hypo-phosphorylated active form of HSF1 and contributes to tumorigenesis. Scientific Reports, 6, 19174; doi: 10.1038/srep19174, 2016.

2015

  1. Xiaoqi Wang, Guangyuan Li, Sanjay Koul, Rieko Ohki, Matthew Maurer, Alain Borczuk, Balazs Halmos. PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling. Oncotarget, DOI: 10.18632/oncotarget.3674.
  2. Toshitsugu Fujita, Miyuki Yuno, Daisuke Okuzaki, Rieko Ohki, and Hodaka Fujii. Identification of non-coding RNAs associated with telomeres by enChIP-RNA-Seq. PLoS One, 10, e0123387, 2015.

2014

  1. Rieko Ohki#, Kozue Saito, Yu Chen, Tatsuya Kawase3, Yukie Aita, Nobuyoshi Hiraoka, Raira Saigawa, Maiko Minegishi, Goichi Yanai, Hiroko Shimizu, Shinichi Yachida, Naoaki Sakata, Akihiko Yokoyama, Ryuichiro Doi, Tomoo Kosuge, Kazuaki Shimada, Benjamin Tycko, Toshihiko Tsukada, Yae Kanai, Shoichiro Sumi, Hideo Namiki, Yoichi Taya, Tatsuhiro Shibata and Hitoshi Nakagama. (#corresponding author) PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors. Proc Natl Acad Sci USA, 111 (23), E2404-E2413, 2014. 

2013

  1. Toshitsugu Fujita, Yoshinori Asano, Junko Ohtsuka, Yoko Takada, Kazunobu Saito, Rieko Ohki, Hodaka Fujii. Identification of telomere-associated molecules by engineered DNA-binding molecule-mediated chromatin immunoprecipitation (enChIP). Scientific Reports, 3, doi:10.1038/srep03171, 2013.  

2011

  1. Chikako Ozeki, Tatsuhiro Shibata, Takashi Kohno, Yuichiro Sawai, Koji Okamoto, Jun Yokota, Fumio Tashiro, Seiichi Tanuma, Ryuichi Sakai, Tatsuya Kawase, Issay Kitabayashi, Yoichi Taya and Rieko Ohki#. (#corresponding author) Cancer susceptibility polymorphism of p53 at codon 72 affects phosphorylation and degradation of p53 protein. Journal of Biological Chemistry, Vol. 286, pp. 18251-18260, 2011.

2009

  1. Tatsuya Kawase*, Rieko Ohki#, *, Tatsuhiro Shibata, Shuichi Tsutsumi, Naoko Kamimura, Johji Inazawa, Tsutomu Ohta, Hitoshi Ichikawa, Hiroyuki Aburatani, Fumio Tashiro and Yoichi Taya. (*These authors equally contributed to the work, #corresponding author) PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell, Vol. 136, pp. 535-550, 2009.

2008

  1. Tatsuya Kawase, Hitoshi Ichikawa, Tsutomu Ohta, Naohito Nozaki, Fumio Tashiro, Rieko Ohki# and Yoichi Taya#. (#corresponding author) p53 target gene AEN is an exonuclease required for p53-dependent apoptosis. Oncogene, Vol. 27, pp. 3797-810, 2008.

2007

  1. Rieko Ohki*, Tatsuya Kawase*, Tsutomu Ohta, Hitoshi Ichikawa and Yoichi Taya. (*These authors equally contributed to the work) Dissecting functional roles of p53 N-terminal transactivation domains by microarray expression analysis. Cancer Science, Vol. 98, pp. 189-200, 2007.

Reviews

  1. 大木理恵子.
    概論—古くても、まだまだ新しい、最も有名ながん抑制遺伝子p53
    実験医学, 35, pp. 2322-2328, 2016.
  2. 川瀬竜也,大木理恵子.
    p53の新たな細胞保護、がん化促進経路.
    実験医学, 35, pp. 2335-2339, 2016.
  3. 滝川雅大, 大木理恵子.
    野生型・変位型p53を標的とした抗がん剤の現状.
    実験医学, 35, pp. 2367-2368, 2016.
  4. Masahiro Takikawa and Rieko Ohki (corresponding author).
    A vicious partnership between AKT and PHLDA3 to facilitate neuroendocrine tumors.
    Cancer Science, 108(6):1101-1108.
  5. IER5は新規の低リン酸化型の活性化HSF1を誘導し、がん化を促進する. 浅野良則, 大木理恵子. 実験医学, 34, pp. 1783-1785, 2016.
  6. 陳 ヨ, 斉藤 梢, 山口 陽子, 大木 理恵子.
    膵神経内分泌腫瘍の新規がん抑制遺伝子PHLDA3の発見.
    胆と膵、Vol.36 No.6、2015 年 6 月: 515-523.
  7. 山口 陽子, 斉藤 梢, 陳 ヨ, 大木 理恵子.
    新規がん抑制遺伝子PHLDA3によるAkt経路の制御機構と治療への展開 −膵神経内分泌腫瘍の個別化医療開発を目指して−.
    実験医学、2014 年 7 月 増刊号: 135-143.
  8. 川瀬竜也、大木理恵子 PHLDA3は新規Akt抑制因子であり、癌化を抑制する因子である
    細胞工学 Special Review, vol. 29, pp. 599-605, 2010
  9. 大木理恵子、川瀬竜也 PHLDA3は新規Akt抑制因子であり、癌化を抑制する因子である
    生体の科学vol. 61, pp. 560-567, 2010
  10. 大木理恵子、田矢洋一 p53によるアポトーシス制御のメカニズム
    バイオ研究マスターシリーズ 細胞死・アポトーシス集中マスター, pp. 71-80, 2006
  11. Rieko Ohki and Fuyuki Ishikawa. Telomerase in cancer and senescence.
    Molecular Medicine, vol. 36, pp. 1316-1323, 1999.
  12. Rieko Ohki and Nobuyuki Tanaka. IRF-1 as a regulator of cell cycle, proliferation and oncogenesis. Experimental Medicine, vol. 15, pp. 1956-1961, 1997.
  13. Ryoiti Kiyama, Shinichi Inoue, Rieko Ohki, Eriko Kikuya, Hiroshi Yokota and Michio Oishi.
    A differential cloning procedure for rearranged or altered genomic DNA based on in-gel competitive reassociation. Advances in Biophysics, vol. 31, pp. 151-161, 1995.